199 related articles for article (PubMed ID: 37266868)
1. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Agilities in the Time of COVID-19: Overview, Trends, and Opportunities.
Bolislis WR; de Lucia ML; Dolz F; Mo R; Nagaoka M; Rodriguez H; Woon ML; Yu W; Kühler TC
Clin Ther; 2021 Jan; 43(1):124-139. PubMed ID: 33353762
[TBL] [Abstract][Full Text] [Related]
3. How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
McGoldrick M; Gastineau T; Wilkinson D; Campa C; Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; de Moraes Stávale MC; Sivaramakrishnan VH; Desai S
Vaccine; 2022 Feb; 40(9):1215-1222. PubMed ID: 35180993
[TBL] [Abstract][Full Text] [Related]
4. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.
Popkin ME; Goese M; Wilkinson D; Finnie S; Flanagan T; Campa C; Clinch A; Teasdale A; Lennard A; Cook G; Mohan G; Osborne MD
AAPS J; 2022 Sep; 24(6):101. PubMed ID: 36168002
[TBL] [Abstract][Full Text] [Related]
5. Regulatory agilities impacting review timelines for Pfizer/BioNTech's BNT162b2 mRNA COVID-19 vaccine: a retrospective study.
Patel P; Macdonald JC; Boobalan J; Marsden M; Rizzi R; Zenon M; Ren J; Chu H; Cappelleri JC; Roychoudhury S; O'Brien J; Izaki-Lee K; Boyce D
Front Med (Lausanne); 2023; 10():1275817. PubMed ID: 38020129
[TBL] [Abstract][Full Text] [Related]
6. Reliance is key to effective access and oversight of medical products in case of public health emergencies.
Saint-Raymond A; Valentin M; Nakashima N; Orphanos N; Santos G; Balkamos G; Azatyan S
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):805-810. PubMed ID: 35945703
[TBL] [Abstract][Full Text] [Related]
7. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements.
Miletic N; Adam S; Acquah J; Aziz Z; Joos A; Mwangi JM
Front Med (Lausanne); 2023; 10():1207954. PubMed ID: 37731723
[TBL] [Abstract][Full Text] [Related]
8. Asia Partnership Conference of Pharmaceutical Associations (APAC) Report on Regulatory Agility Implemented During the COVID-19 Pandemic: Inspiring Partnerships and Recommendations for the Way Forward.
Chong SSF; Kanno M; Chee ASM; Long SM; Ong SHM; Harnpramukkul U; Binos RSR
Ther Innov Regul Sci; 2023 Jan; 57(1):12-25. PubMed ID: 36175790
[TBL] [Abstract][Full Text] [Related]
9. The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting.
Mofid S; Bolislis WR; Brading C; Hamilton N; Hardit C; Nagaoka M; Parain J; Zanta M; Kühler TC
Clin Ther; 2021 Dec; 43(12):2046-2063. PubMed ID: 34740466
[TBL] [Abstract][Full Text] [Related]
10. How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
McGoldrick M; Gastineau T; Wilkinson D; Campa C; De Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Wauters F; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; Collaço de Moraes Stávale M; Sivaramakrishnan VH; Desai S
Vaccine; 2022 Feb; 40(9):1223-1230. PubMed ID: 35180994
[TBL] [Abstract][Full Text] [Related]
11. Worldwide Regulatory Reliance: Launching A Pilot on A Chemistry, Manufacturing and Control Post Approval Change for A Vaccine.
Gastineau T; Ban C; Basso A; Brehme F; Silva AL; Faure O; Le Palaire L; Persaud P; Rodriguez H
PDA J Pharm Sci Technol; 2023 Nov; ():. PubMed ID: 37973190
[TBL] [Abstract][Full Text] [Related]
12. Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide : Joint Position from EFPIA, IFPMA and Vaccines Europe.
Deavin A; Adam S; Ausborn S; Nielsen ASB; Cappellini S; Colmagne-Poulard I; Gastineau T; Gonzalez-Martinez A; Meillerais S; Mortazavi C
Ther Innov Regul Sci; 2023 Jan; 57(1):7-11. PubMed ID: 35917091
[TBL] [Abstract][Full Text] [Related]
13. Clinical development and approval of COVID-19 vaccines.
Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P
Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542
[TBL] [Abstract][Full Text] [Related]
14. Reliance: a smarter way of regulating medical products - The IPRP survey.
Doerr P; Valentin M; Nakashima N; Orphanos N; Santos G; Balkamos G; Saint-Raymond A
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):173-177. PubMed ID: 33355025
[No Abstract] [Full Text] [Related]
15. How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action.
Janssens R; Barbier L; Muller M; Cleemput I; Stoeckert I; Whichello C; Levitan B; Hammad TA; Girvalaki C; Ventura JJ; Bywall KS; Pinto CA; Schoefs E; Katz EG; Kihlbom U; Huys I
Front Pharmacol; 2023; 14():1192770. PubMed ID: 37663265
[No Abstract] [Full Text] [Related]
16. Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry.
Higgins MF; Abu-Absi N; Gontarz E; Gorr IH; Kaiser K; Patel P; Ritacco F; Sheehy P; Thangaraj B; Gill T
Biotechnol Prog; 2023 Mar; 39(2):e3321. PubMed ID: 36546782
[TBL] [Abstract][Full Text] [Related]
17. Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.
Kürzinger ML; Douarin L; Uzun I; El-Haddad C; Hurst W; Juhaeri J; Tcherny-Lessenot S
Ther Adv Drug Saf; 2020; 11():2042098620976951. PubMed ID: 33343857
[TBL] [Abstract][Full Text] [Related]
18. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
Pagliusi S; Hayman B; Jarrett S
Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
[TBL] [Abstract][Full Text] [Related]
19. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?
Klein K; Stolk P; Tellner P; Acha V; Montagne S; Stöckert I
Ther Innov Regul Sci; 2022 Mar; 56(2):366-377. PubMed ID: 35129827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
